LMS to delist from Amex

Friday, May 2, 2008 General News J E 4
MONTREAL, May 1 /PRNewswire-FirstCall/ - LMS Medical Systems (TSX: LMZ,AMEX: LMZ), a healthcare technology company and developer of the CALM- patientsafety software system for obstetrics, today announced that its Board ofDirectors has unanimously decided to delist the Company's common shares fromAmex.

The decision is in keeping with the Company's previous announcement tostreamline operations and control costs in order to become cash flow positive.It is expected that Amex trading will cease on or about May 22, 2008.

LMS common shares will continue to be traded on the Company's principalexchange, the TSX.

About LMS: LMS is a leader in the application of advanced mathematicalmodeling and neural networks for medical use. The LMS CALM Suite providesphysicians, nursing staff, risk managers and hospital administrators withclinical information systems and risk management tools designed to improveoutcomes and patient care for mothers and their infants during childbirth.

Except for historical information contained herein, the matters discussedin this news release are forward-looking statements. Because theseforward-looking statements involve risks and uncertainties, there areimportant factors that could cause actual results to differ materially fromthose expressed implied by the forward-looking statements including, butwithout limitation, economic conditions in general and in the healthcaremarket, the demand for and market for our products in domestic andinternational markets, our current dependence on the CALM product suite, thechallenges associated with developing new products and obtaining regulatoryapprovals if necessary, research and development activities, the uncertaintyof acceptance of our products by the medical community, the lengthy salescycle for our products, third party reimbursement, competition in our markets,including the potential introduction of competitive products by others, ourdependence on our distributors, physician training, enforceability and thecosts of enforcement of our patents, potential infringements of our patentsand the other factors set forth from time to time in the Company's filingswith the United States Securities and Exchange Commission and with theCanadian Securities Commissions. The Company has no intention of or obligationto update or revise any forward-looking statements, whether as a result of newinformation, future events or otherwise.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Proteolix Initiates Phase 2 Clinical Trial of Carf...
Thermo Fisher Scientific to Host Analyst Meeting